|
|
 |
|
Viewing report
|
|
|
|
Systems Biology in Biotech and Pharma: A New Paradigm for Innovation
Biopharm Knowledge Publishing, July 2009, Pages: 230
Growth in the pharmaceutical market has slowed – almost to a standstill. One reason is that governments and other payers are cutting costs in a faltering world economy.
But a more fundamental problem is the failure of major companies to discover, develop and market new drugs. Major drugs losing patent protection or being withdrawn from the market are simply not being replaced by new therapies – the pharmaceutical market model is no longer functioning effectively and most pharmaceutical companies are failing to produce the innovation needed for success.
This new report looks at a vital strategy which can bring innovation to a market in need of new ideas and new products - Systems Biology.
Systems Biology employs a rational approach, via a mix of analytical and systemic routes, to delineate the emerging properties of biological networks. It aims to explain and predict, quantitatively, molecular, cellular, tissue, organ and whole-body processes. By using multi-scale models in silico, Systems Biology is expected to bring numerous benefits to pharmaceutical discovery and development as the properties of a system can be studied over a wide range of length and time scales.
Systems Biology can reduce the number of compounds that need to be synthesised in discovery by using refined algorithms to weed out compounds with poor pharmacokinetic of toxicology profiles. And it will save time and money by selecting the drugs which are more likely to succeed in clinical development.
This new 230 page report is written by industry and academic expert Dr Ales Prokop, one of the leading researchers in Systems Biology. It will enable you to:
- Understand the nature and processes involved in Systems Biology
- See how its benefits relate to pharmaceutical innovation
- Delineate the costs and cost savings involved
- Understand why Systems Biology improves on current approaches to drug discovery
- Relate Systems Biology to advances in genetic profiling and personalised medicine
Contents include:
- Tools and lead optimisation
- Virtual chemistry screening
- Lead discovery and molecular interactions
- In silico screening
- Computational Systems Biology in cell biology
- Pharmacology and pharmacokinetics
- Formulation and production
- Model-based drug development
Systems Biology is essential reading for corporate management and those in product, process and analytical discovery and development, product quality and characterisation, R&D, and regulatory affairs. It is aimed at biotech, big pharma, producers of biosimilars, contract manufacturers, providers of analytical services, and clinical research organizations. This report gives an authoritative, detailed and clear explanation of the issues surrounding Systems Biology, its implications for the market and for the biotech and pharmaceutical industries.
Customers who bought this item also bought
Bioinformatics in Drug Discovery
Proteomics - Technologies, Markets and Companies
Innovations In Epigenetics: Advances in Technologies, Diagnostics & Therapeutics
Nanobiotechnology Applications, Markets and Companies
Lead Optimization Strategies: Future Developments, Threats and Opportunities For Big Pharma, Specialty Pharma and Biotech
Predictive ADME and Toxicology Strategies: Challenges and Opportunities for In Vivo, In Vitro and In Silico Predictive Technologies
The Future of Systems Biology: Emerging Technologies and their Impact on Drug Discovery, Development and Diagnostics
Innovations in Bioinformatics: Emerging Tools for Drug Discovery and Development
Biomarkers - Technologies, Markets and Companies
Cytogenetics - Technologies, Markets and Companies
|
|
|
|
